Literature DB >> 8511741

Treatment of resistant pain in hypertrophic pulmonary arthropathy with ketorolac.

N Blackwell1, L Bangham, M Hughes, D Melzack, I Trotman.   

Abstract

Pain associated with hypertrophic pulmonary osteoarthropathy (HPOA) may be extremely disabling and resistant to treatment. The successful use of ketorolac, a new non-steroidal anti-inflammatory drug, given by subcutaneous infusion is reported in two patients with uncontrolled pain caused by HPOA.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8511741      PMCID： PMC464442          DOI： 10.1136/thx.48.4.401

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


  3 in total

Review 1.  Ketorolac. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  M M Buckley; R N Brogden
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

Review 2.  Ketorolac, an injectable nonnarcotic analgesic.

Authors:  K M Litvak; G K McEvoy
Journal:  Clin Pharm       Date:  1990-12

Review 3.  Hypertrophic pulmonary osteoarthropathy in pulmonary metastatic disease. A case report and review of the literature.

Authors:  R A Davies; M Darby; M A Richards
Journal:  Clin Radiol       Date:  1991-04       Impact factor: 2.350
  3 in total
  4 in total

Review 1.  Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management.

Authors:  J C Gillis; R N Brogden
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

2.  The role of subcutaneous ketorolac for pain management.

Authors:  Mary E Vacha; Wennie Huang; Jennifer Mando-Vandrick
Journal:  Hosp Pharm       Date:  2015-02

3.  Hypertrophic osteoarthropathy presenting as unilateral cellulitis with successful treatment using pamidronate disodium.

Authors:  Sebastian G Bernardo; Jason J Emer; Mark E Burnett; Marsha Gordon
Journal:  J Clin Aesthet Dermatol       Date:  2012-09

Review 4.  Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy.

Authors:  Sheila Nguyen; Mehrnaz Hojjati
Journal:  Clin Rheumatol       Date:  2010-10-09       Impact factor: 2.980
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.